Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Tanvex BioPharmaTPE:6541 +3.20%41 Debt-to-Equity is 0.31 as of Mar. 2026, which is 3% below its 10-year median of 0.32. GuruFocus rates TPE:6541 with a GF Score™ of 41/100. The stock has 3 warning signs investors should review. Among 959 Biotechnology companies, Tanvex BioPharma ranks worse than 64.23% on this metric.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for Tanvex BioPharma's Debt-to-Equity or its related term are showing as below:
TPE:6541'
s Debt-to-Equity Range Over the Past 10 Years
Min: 0 Med: 0.32 Max: 5.25
Current: 0.31
During the past 13 years, the highest Debt-to-Equity Ratio of Tanvex BioPharma was 5.25. The lowest was 0.00. And the median was 0.32.
TPE:6541's Debt-to-Equity is ranked worse than 64.23% of 959
companies
in the Biotechnology industry
Industry Median: 0.15
vs TPE:6541: 0.31
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
Tanvex BioPharma Debt-to-Equity Related Terms
Tanvex BioPharma Debt-to-Equity Historical Data
* Premium members only.
The historical data trend for Tanvex BioPharma's Debt-to-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TPE:6541 vs VRTX, REGN, RVMD: Debt-to-Equity Comparison
For the Biotechnology subindustry, Tanvex BioPharma's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Tanvex BioPharma Debt-to-Equity vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Tanvex BioPharma's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where Tanvex BioPharma's Debt-to-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Tanvex BioPharma (TPE:6541) has a Debt-to-Equity of 0.31 as of Mar. 2026. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Tanvex BioPharma and its competitors. This is near median its historical median of 0.32. According to the industry distribution chart, Tanvex BioPharma ranks #616 out of 959 companies in the Biotechnology industry, placing it in the top 64.2%.
Is Tanvex BioPharma's Debt-to-Equity too high?
Tanvex BioPharma's current Debt-to-Equity of 0.31 is near median its 10-year median of 0.32. The Biotechnology industry median Debt-to-Equity is 0.15. Tanvex BioPharma's value of 0.31 is 106.7% above this industry median. Based on the distribution chart, Tanvex BioPharma ranks #616 out of 959 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Tanvex BioPharma has a GF Score™ of 41/100, reflecting its overall financial health beyond just this single metric.
How does Tanvex BioPharma's Debt-to-Equity compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Tanvex BioPharma ranks #616 out of 959 companies for Debt-to-Equity. This places Tanvex BioPharma in the lower half of its industry. The industry median Debt-to-Equity is 0.15. Tanvex BioPharma's value of 0.31 is 106.7% above this benchmark. While the company's 10-year median is 0.32 vs. the industry median of 0.15, Tanvex BioPharma has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Biotechnology company?
The median Debt-to-Equity among Biotechnology companies is 0.15, based on 959 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Tanvex BioPharma's current Debt-to-Equity of 0.31 is 106.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Tanvex BioPharma and its competitors. For the Biotechnology industry, the median Debt-to-Equity is 0.15 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Tanvex BioPharma's current Debt-to-Equity is 0.31, which is near median its own 10-year median of 0.32. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Tanvex BioPharma stock overvalued right now?
Tanvex BioPharma (TPE:6541) has a current Debt-to-Equity of 0.31. The current Debt-to-Equity is 0.31, which is near median its 10-year median of 0.32 and 106.7% above the Biotechnology industry median of 0.15. Tanvex BioPharma's overall GF Score™ is 41/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For Tanvex BioPharma (TPE:6541), the current Debt-to-Equity is 0.31 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Tanvex BioPharma Inc is a biopharmaceutical company. It is engaged in the research, development, manufacture, and sale of biosimilar products and contract development and manufacturing of biological medicine. The company's products are used to cure diseases such as Neutropenia, Breast Cancer, Metastatic Colorectal Cancer, and others. Geographically, the company operates in Asia, America, Europe, and Australia. The company generates a majority of its revenue from the USA.
41GF Score
Get the complete analysis for TPE:6541
Debt-to-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TPE:6541 has been successfully added to your 
